



Developing Countries Vaccine  
Manufacturers Network




# 23rd Annual General Meeting



20th–22nd October, 2022  
Pune, INDIA

Global Equity & Timely Access of Vaccines



**DRAFT AGENDA AT A GLANCE**  
**20<sup>th</sup>–22<sup>nd</sup> October, 2022**  
**Pune, INDIA**

<b>DAY 1</b> <b>Thursday</b> <b>20<sup>th</sup> October</b>	<b>DAY 2</b> <b>Friday</b> <b>21<sup>st</sup> October</b>	<b>DAY 3</b> <b>Saturday</b> <b>22<sup>nd</sup> October</b>
<b>Registration &amp; Rapid Antigen Testing</b>		
DCVMN General Assembly (for members only)	Africa Forum: Kick the Tyres	Roadmap to Future Vaccines
<b>Exhibition Viewing &amp; Networking</b>		
Inaugural Session	Sustainability and Lessons Learnt	Capacity Building: Connect to Protect
<b>Exhibition Viewing &amp; Networking</b>		
Pandemic Preparedness Response	Global Equity & Timely Access of Vaccines	Key Learnings from Working Groups (by DCVMN)
<b>Exhibition Viewing &amp; Networking</b>		
CEO'S Report	Regulatory & PQ	Innovative Technologies (by Sponsors)
<b>Exhibition Viewing &amp; Networking</b>		
	Innovation in Finance & Technology	CEO Forum: Horizon 2030
Networking Dinner	Cocktails Cultural Program Gala Dinner	Networking Dinner
<b>End of AGM Day 1</b>	<b>End of AGM Day 2</b>	<b>End of AGM</b>

\*to be confirmed

<b>Detailed Draft Agenda</b> <b>20<sup>th</sup>–22<sup>nd</sup> October, 2022, Pune, INDIA</b>	
<b>IST</b>	<b>AGM Day 1 (Thursday, 20<sup>th</sup> October, 2022)</b>
<b>0900 – 1100</b>	<b>Attendee and Speaker Registrations</b>
<b>1100 – 1300</b>	<b>DCVMN General Assembly (for members only)</b>
<b>1300 – 1400</b>	<b>Lunch</b>
<b>1400 – 1530</b>	<p><b>Inaugural Session</b></p> <p><b>Lighting of Lamp by Chief Guest, Dr. Mansukh Mandaviya, Honorable Union Minister for Health &amp; Family Welfare and Chemicals &amp; Fertilizers, Government of India</b></p> <p><b>Opening Address:</b> Mr. Adar C. Poonawala, CEO-SII</p> <p><b>Initiation of Ceremony:</b> Mr. Rajinder Suri, CEO-DCVMN</p> <p><b>Welcome to the session:</b> Mr. Sai D. Prasad, Board Chair-DCVMN</p> <p><b>Key note Speakers:</b></p> <ul style="list-style-type: none"> <li>• Dr. Tedros Adhanom Ghebreyesus, Director General, WHO</li> <li>• Dr. Ayoade Alakija, WHO Special Envoy for the ACT–Accelerator</li> <li>• Dr. Seth Berkley, CEO, GAVI</li> <li>• Dr. Richard Hatchett, CEO, CEPI</li> <li>• Dr. Bruce Aylward, Special Advisor to DG–WHO</li> <li>• Dr. Soumya Swaminathan, Chief Scientist, WHO</li> <li>• Dr. Carissa F. Etienne, Director-PAHO</li> <li>• Mr. Nikolaj Gilbert, President &amp; CEO of PATH</li> </ul> <p><b>Inaugural address:</b> Chief Guest, Honorable Dr. Mansukh Mandaviya, Union Minister for Health &amp; Family Welfare and Chemicals &amp; Fertilizers, Government of India</p> <p><b>Vote of thanks</b></p>
<b>1530 – 1600</b>	<b>Coffee Break: Exhibition Viewing &amp; Networking</b>
<b>1600 – 1730</b>	<p><b>Session – 2: Pandemic Preparedness Response</b></p> <p><b>Chair – Prof. Helen Rees, Founder &amp; Chairperson WITS RHI</b></p> <ul style="list-style-type: none"> <li>• Dr. Kerim Chitour, Global Head of Clinical, Center for Vaccine Innovation and Access, PATH</li> <li>• Mr. Thomas B. Cueni, DG, IFPMA</li> <li>• Dr. Michelle McMurry–Heath, President &amp; CEO, BIO*</li> <li>• Dr. Robin Moudy, HHS OGA Pandemics &amp; Emerging Threats, U.S. Department of Health and Human Services</li> <li>• Dr. Adam Hacker, Director Regulatory Affairs, CEPI</li> <li>• Mr. Farid Fezoua, Global Director - Health &amp; Education Department, IFC/World Bank</li> <li>• Dr. Marie Mazur, Director, Ready2Respond</li> <li>• Dr. Akira Homma, Senior Advisor, Bio-Manguinhos/Fiocruz</li> </ul> <p>Audience Q&amp;A</p>
<b>1730 – 1800</b>	<b>DCVMN CEO'S Report &amp; New Board Introduction</b>
<b>1900 – 2200</b>	<b>Networking Dinner</b>
<b>End of AGM Day 1</b>	

\*to be confirmed

AGM Day 2 (Friday, 21 <sup>st</sup> October, 2022)	
IST	AGM Day 2 (Friday, 21 <sup>st</sup> October, 2022)
<b>0800 – 0900</b>	<b>Attendee and Speaker Registrations</b>
<b>0900 – 1030</b>	<p><b>Session 1: Africa Forum: ‘Kick the Tyres’ (Panel discussion)</b>  <b>Chair – Dr Ayoade Alakija, WHO Special Envoy for the ACT–Accelerator</b></p> <ul style="list-style-type: none"> <li>• Dr. Nicaise Ndembi, Senior Science Advisor, Africa Centre for Disease Control and Prevention (Africa CDC)</li> <li>• Dr. Matthew Downham, Director Manufacturing &amp; Supply Chain Networks, CEPI</li> <li>• Dr. Simone Blayer, Global Head, Chemistry, Manufacturing, Control and Nonclinical Toxicology, PATH</li> <li>• Prof Nico Vandaele, Access-To-Medicines Research Centre, KU Leuven, Belgium</li> <li>• Dr. Morena Makhoana, CEO, Biovac</li> <li>• Dr. Amadou Alpha Sall, CEO, Institut Pasteur de Dakar</li> <li>• Prof. Petro Terblanche, MD, Afrigen Biologics</li> </ul> <p>Audience Q&amp;A</p>
<b>1030 – 1130</b>	<p><b>Session 2: Sustainability and Lessons Learnt</b>  <b>Chair – Ms. Julia Kuhn, Officer, Strategy Planning and Management, BMGF</b></p> <ul style="list-style-type: none"> <li>• Dr. Martin Nicholson, Vaccine Manufacturing Expert, WHO</li> <li>• Dr. Claudia Nannei, Senior Technical Officer, WHO</li> <li>• Dr. Chris Chadwick, Technical Officer for Influenza Preparedness and Response, WHO</li> <li>• Ms. Frauke Uekermann, Associate Director of Vaccine Markets, CHAI</li> <li>• Dr. Heba Wali, Chairman, VacSera</li> <li>• Dr. Stavros Nicolaou, Group Senior Executive Strategic Trade, Aspen Pharma</li> <li>• Mr. Patrick Tippoo, Head of Science and Innovation, Biovac</li> </ul> <p>Audience Q&amp;A</p>
<b>1130 – 1200</b>	<b>Coffee Break, Exhibition Viewing &amp; Networking</b>
<b>1200 – 1300</b>	<p><b>Session 3: Global Equity &amp; Timely Access of Vaccines</b>  <b>Chair – Dr. Derrick Sim, Managing Director, Office of the COVAX Facility</b></p> <ul style="list-style-type: none"> <li>• Mr. Andrew Owain Jones, Principal Advisor &amp; Chief Vaccine Center, UNICEF-SD</li> <li>• Ms. Tania Cernuschi, Unit Head–Agenda, Policy &amp; Strategy (APS), Department of Immunization, Vaccines &amp; Biologicals (IVB), Universal Health Coverage/Lifecourse Division, WHO</li> <li>• Ms. Nafisa Jiwani, Managing Director, Global Health Initiatives US International Development Finance Corporation (DFC)</li> <li>• Mr. Ruchir Agarwal, Fellow, Harvard Business School</li> <li>• Mr. Harish Iyer, Deputy Director Health &amp; Innovation, BMGF</li> <li>• Ms. Zeynep Kantur, Global Manager - Health &amp; Education, IFC/World Bank Group</li> <li>• Prof. Padmashree Gehl Sampath, Senior Advisor to the President Pharmaceuticals and Health, Office of the President, AfDB Group</li> </ul>

\*to be confirmed

	Audience Q&A
<b>1300 – 1400</b>	<b>Lunch, Exhibition Viewing &amp; Networking</b>
<b>1400 – 1530</b>	<p><b>Session 4: Regulatory &amp; PQ</b> <b>Chair – Dr. Mariângela Batista Galvão Simão, Assistant Director-General, Access to Medicines and Health Products, WHO</b></p> <ul style="list-style-type: none"> <li>• Dr. VG Somani, DCGI, India*</li> <li>• Dr. Rogério Paulo Pinto de Sá Gaspar, Director-Regulation and Prequalification, WHO</li> <li>• Mr. Deusdedit Mubangizi, Unit Head Prequalification Unit (PQT) Regulation &amp; Prequalification Department, WHO</li> <li>• Dr. Siti Asfijah Abdoellah, Director for Drug Registration, BPOM, Indonesia</li> <li>• Dr. Boitumelo Semete Makokotlela, CEO, South African Health Products Regulator, NRA – South Africa</li> <li>• Prof. Narendra K Arora, Executive Director, INCLEN Trust International, India</li> <li>• Prof. Pieter Neels, Chair Human Vaccine Committee, IABS Director Vaccine Advice BV</li> <li>• Dr. Hiiti Sillo, Unit Head, Regulation and Safety, Department of Regulation and Prequalification, WHO</li> </ul> <p>Audience Q&amp;A</p>
<b>1530 – 1600</b>	<b>Coffee Break, Exhibition Viewing &amp; Networking</b>
<b>1600 – 1740</b>	<p><b>Session 5: Innovation in Finance &amp; Technology</b> <b>Chair – Mr. James C. Polan, Vice President of Development Credit, US International Development Finance Corporation (DFC)</b></p> <ul style="list-style-type: none"> <li>• Dr. Raman Rao, CEO, Hilleman Laboratories, Singapore</li> <li>• Mr. Brandon Ball, Head of Government Affairs, Temptime - Vaccine Vial Monitors: Lessons learned and what's next in a post-COVID landscape</li> <li>• Mr. Andrew Wong, Director of Business Development, Walvax; CEO, Shanghai Wotai Biotech.</li> <li>• Dr. Kutub Mahmood, Project Director, sIPV and NGS Projects, PATH</li> <li>• Dr. Andreas Castan, Director Strategic Technologies Cytiva - Idea to Injection: Flexible and modular platforms to optimize your manufacturing</li> <li>• Prof. Calman A. MacLennan, Shigella Project, BMGF - Novel Shigella vaccine technologies &amp; progress towards licensure</li> <li>• Mr. Vikrant Hedau, Technical Support Manager, Tofflon - Tofflon Integrated Platform for Fast-Track Vaccine Project</li> </ul> <p>Audience Q&amp;A</p>
<b>1740 – 1800</b>	<b>Wrap-Up by Mr. Patrick Tippoo, Deputy Chair, DCVMN Board</b>
<b>1930 – 2015</b>	<b>Cocktails</b>
<b>2015 – 2100</b>	<b>Cultural Program by The Shiamak Davar Dance Company</b>
<b>2100 – 2300</b>	<b>Gala Dinner</b>
<b>End of AGM Day 2</b>	

\*to be confirmed

IST	AGM Day 3 (Saturday, 22 <sup>nd</sup> October, 2022)
0800 – 0900	<b>Attendee and Speaker Registrations</b>
0900 – 1000	<p><b>Session 1: Roadmap to Future Vaccines</b>  <b>Chair – Dr. Birgitte K. Giersing, Team Lead, Vaccine Prioritization &amp; Platforms, WHO</b></p> <ul style="list-style-type: none"> <li>• Prof. Gagandeep Kang, The Wellcome Trust Research Laboratory, Christian Medical College Vellore</li> <li>• Prof. Kamel Senouci, Director, ADVAC University</li> <li>• Dr. Prashant Yadav, Senior Fellow, Center for Global Development</li> <li>• Mr. Sai D Prasad, Executive Director, Bharat Biotech</li> </ul> <p>Audience Q&amp;A</p>
1000 – 1125	<p><b>Session 2: Capacity Building – Connect to Protect (Technical)</b>  <b>Chair – Ms. Tania Cernuschi, Unit Head–Agenda, Policy &amp; Strategy (APS), Department of Immunization, Vaccines &amp; Biologicals (IVB), Universal Health Coverage/Lifecourse Division, WHO</b></p> <ul style="list-style-type: none"> <li>• Dr. Jicui Dong, Head, LPA Unit, Regulation &amp; PQ, Access to Medicines and Health Products Division, WHO</li> <li>• Ms. Emma Wheatley, Director, Access and Private Partnerships, CEPI</li> <li>• Mr. David Muterandu / Ms. Ann Ottosen, UNICEF</li> <li>• Ms. Christina Liu, Technical Officer, Immunization Agenda, Policy, and Strategy, WHO</li> <li>• Ms. Alice Ma, Senior Analyst Market Shaping, GAVI</li> </ul> <p><b>Capacity Building – Connect to Protect (Human Capital)</b></p> <ul style="list-style-type: none"> <li>• Ms. Julia Kuhn, Officer, Strategy Planning and Management, BMGF</li> <li>• Ms. Amanda Zehnder, Senior Organization Development and Change Management Advisor – CVIA</li> <li>• Mr. John Balchunas, Workforce Director, NIIMBL</li> </ul> <p>Audience Q&amp;A</p>
1125 – 1145	<b>Coffee Break, Exhibition Viewing &amp; Networking</b>
1145 – 1300	<p><b>Session 3: Key Learnings from Working Groups (by DCVMN)</b>  <b>Chair – Mr. Fernando Lobos &amp; Mr. Tiago Rocca – DCVMN Board Members</b></p> <ul style="list-style-type: none"> <li>• Supply Chain Working Group – Ms. Rachel Park</li> <li>• Regulatory Affairs Working Group – Mr. Parag Nagarkar</li> <li>• Pharma-co-Vigilance Working Group – Ms. Viska Indriani</li> <li>• COVID Committee – Mr. Adriansjah Azhari</li> <li>• 3Rs / PSPT Working Group – Dr. Pradip Das</li> <li>• DCVMN Update</li> </ul> <p>Audience Q&amp;A</p>
1300 – 1400	<b>Lunch, Exhibition Viewing &amp; Networking</b>

\*to be confirmed

<p>1400 – 1530</p>	<p><b>Session 4: Innovative Technologies - Exhibitors and Sponsors presentations</b> <b>Chair – Prof. Petro Terblanche, Managing Director, Afrigen Biologics</b></p> <ul style="list-style-type: none"> <li>• Merck Life Sciences - Dr. Subhasis Banerjee, Principal Application Expert- Bioprocessing in Asia Pacific- Chromatographic purification of plasmid DNA</li> <li>• Sartorius – Ms. Raman Rani, Manager – Bioprocess Application Services <i>Topic – Accelerating Vaccine Manufacturing using Sartorius Solutions</i></li> <li>• Bio-Engineering – Dr. Shaobin Mike Lu, International Sales Manager <i>Topic – Solutions for large FMD vaccine production</i></li> <li>• Biozeen – Mr. Devak Padmanabhan MK, Quality Assurance Leader &amp; Management Representative for Quality Systems <i>Topic – Biozeen's approach towards Pharma 4.0 and going paperless</i></li> <li>• Univercells Technologies - Mr. Pratik Gajjar, Senior Bioprocess Specialist <i>Topic - An innovative platform for integrated continuous vaccine production</i></li> <li>• Telstar – Mr. Surajit Chandra, Sales Manager India <i>Topic - Process Equipment involved in Vaccine Production</i></li> <li>• Stevanto Group – Mr. Seshu Tirumala, National Sales Manager <i>Topic - Managing complexity, delivering value</i></li> <li>• Pharmajet - Ms. Ozge Goktekin, Managing Director Europe &amp; Asia <i>Topic- Improved Vaccine and Therapeutic Performance...without the Jab</i></li> <li>• Truking Technology – Mr. Rajkumar Gaikwad <i>Topic- Truking Integrated Solutions: Process intensification and Straight through processing solutions for vaccine manufacturing</i></li> </ul> <p>Audience Q&amp;A</p>
<p>1530 – 1600</p>	<p><b>Coffee Break, Exhibition Viewing &amp; Networking</b></p>
<p>1600 – 1730</p>	<p><b>Session 5: CEO Forum: Horizon 2030</b> <b>Chair – Dr. Krishna Ella, Founder, Chairman &amp; MD, Bharat Biotech</b></p> <ul style="list-style-type: none"> <li>• Mr. Adar C. Poonawalla, CEO, Serum Institute of India</li> <li>• Dr. Rajesh Jain, Managing Director, Panacea Biotec*</li> <li>• Ms. Mahima Datla, Managing Director, Bio E</li> <li>• Mr. Abdul Muktaadir, Chairman &amp; Managing Director, Incepta</li> <li>• Prof. Mauricio Zuma Medeiros, Director, Bio FioCruz</li> <li>• Dr. Morena Makhoana, CEO, Biovac</li> <li>• Dr. Ke Wu, Founder &amp; CEO, Bravovax</li> <li>• Mr. K. Anand Kumar, MD, Indian Immunological</li> <li>• Mr. Rahman Roestan, Operations Director, PT Bio Pharma</li> <li>• Mr. Fernando Lobos, Business Development Director, Sinergium Biotech</li> </ul> <p>Audience Q&amp;A</p>
<p>1730 – 1800</p>	<p><b>Wrap up by Mr. Rajinder Suri, CEO-DCVMN</b></p>
<p>1900 – 2200</p>	<p><b>Networking Dinner</b></p>
<p style="text-align: center;"><b>End of AGM</b></p>	

\*to be confirmed

**A few things to note:**

- COVID-19 protocols will be followed. Masks are required to be worn. You are requested to get yourself tested for COVID 19 at the free testing facility available on site.
- This is a hybrid event. Some speakers shall be joining virtually.
- The event will be video recorded.
- Speakers are advised to arrive at the venue 20 minutes prior to their session. This will allow the debriefing time before their onstage session and affix the microphones.
- Once inside the main auditorium, speakers are requested to proceed towards the desk marked session speakers. A DCVMN representative will greet them and escort to the green room.
- **Please share a mobile number** where we can reach you right before your session so we are able to communicate with you if needed (via text message or WhatsApp).

\*to be confirmed